A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

BACKGROUND: Crohn's disease (CD) is a severe, lifelong disease characterised by inflammation of the gastrointestinal mucosa. The impact on patients and society is high as ill health can be lifelong and can negatively affect patients' quality of life. Costs to the NHS are high, particularly...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Health Technol Assess
Auteurs principaux: Dretzke, J, Edlin, R, Round, J, Connock, M, Hulme, C, Czeczot, J, Fry-Smith, A, McCabe, C, Meads, C
Format: Artigo
Langue:Inglês
Publié: NIHR Journals Library 2011
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4781107/
https://ncbi.nlm.nih.gov/pubmed/21291629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta15060
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires